New research published in Nature Cardiovascular Research by the University of Chicago Medicine uncovers a surprising genetic and molecular link between heart failure and atrial fibrillation, suggesting the two cardiovascular conditions may be more interconnected than previously understood.
The study identifies TBX5, a transcriptional regulator, as a critical gene influencing both conditions. Reduced TBX5 in the atria disrupts gene expression, contributing to the development of atrial fibrillation in patients with heart failure. Further analysis revealed that over 100 transcription factors are similarly altered in both conditions, indicating a coordinated genetic response across multiple atrial cell types, including cardiomyocytes and fibroblasts.
“This coordinated change in transcription factors leads us to conclude that atrial fibrillation is not really a different disease than heart failure; it is essentially ‘atrial heart failure,’” said Ivan Moskowitz, MD, PhD, senior author and pediatric cardiologist at UChicago Medicine. “Rather than just a rhythm disorder, atrial fibrillation may reflect atrial muscle dysfunction similar to ventricular dysfunction in heart failure.”
The findings challenge conventional approaches to treating atrial fibrillation, which primarily focus on controlling heart rhythm. The study suggests that addressing the upstream molecular and genetic pathways in the atrium could open new avenues for therapy, similar to treatment strategies used for heart failure.
Researchers at UChicago Medicine are continuing to investigate signaling pathways disrupted by TBX5 deficiency and exploring potential interventions to prevent atrial fibrillation.
“This intersection between heart failure and atrial fibrillation provides a fertile ground for insights and potential treatments,” Moskowitz added. “Our work lays the foundation for a new understanding of atrial disease and its management.”
